TSHA Key Statistics, Chart & Performance
The current stock price of TSHA is 5.745 USD. In the past month the price increased by 39.86%. In the past year, price increased by 234.86%.
TSHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.76B | ||
| AMGN | AMGEN INC | 15.19 | 178.91B | ||
| GILD | GILEAD SCIENCES INC | 15.44 | 156.88B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.4 | 116.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.42 | 82.42B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 786.24 | 52.97B | ||
| INSM | INSMED INC | N/A | 37.07B | ||
| NTRA | NATERA INC | N/A | 32.29B | ||
| BIIB | BIOGEN INC | 10.41 | 25.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.57 | 22.24B | ||
| INCY | INCYTE CORP | 15.61 | 19.68B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.30B |
Related stock screener links
About TSHA
Company Profile
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
Company Info
TAYSHA GENE THERAPIES INC
3000 Pegasus Park Drive, Suite 1430
Dallas TEXAS 75247 US
CEO: RA Session
Employees: 73
Phone: 12146120000
TAYSHA GENE THERAPIES INC / TSHA FAQ
What does TAYSHA GENE THERAPIES INC do?
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 73 full-time employees. The company went IPO on 2020-09-24. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The firm is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. The company has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
What is the stock price of TAYSHA GENE THERAPIES INC today?
The current stock price of TSHA is 5.745 USD. The price decreased by -1.96% in the last trading session.
Does TSHA stock pay dividends?
TSHA does not pay a dividend.
What is the ChartMill rating of TAYSHA GENE THERAPIES INC stock?
TSHA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does TAYSHA GENE THERAPIES INC have?
TAYSHA GENE THERAPIES INC (TSHA) currently has 73 employees.
Can you provide the market cap for TAYSHA GENE THERAPIES INC?
TAYSHA GENE THERAPIES INC (TSHA) has a market capitalization of 1.57B USD. This makes TSHA a Small Cap stock.
TSHA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TSHA. When comparing the yearly performance of all stocks, TSHA is one of the better performing stocks in the market, outperforming 98.81% of all stocks.
TSHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TSHA. While TSHA seems to be doing ok healthwise, there are quite some concerns on its profitability.
TSHA Financial Highlights
Over the last trailing twelve months TSHA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -152.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.57% | ||
| ROE | -45.63% | ||
| Debt/Equity | 0.23 |
TSHA Forecast & Estimates
19 analysts have analysed TSHA and the average price target is 10.78 USD. This implies a price increase of 87.69% is expected in the next year compared to the current price of 5.745.
For the next year, analysts expect an EPS growth of -2.89% and a revenue growth -20.9% for TSHA